Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given an average recommendation of “Hold” by the twenty ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have given a buy recommendation to […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 27,630,000 shares, a growth of 7.6% from the July 15th total of 25,670,000 shares. Based on an average daily trading volume, of 2,150,000 shares, the days-to-cover ratio is presently […]
Fate Therapeutics (NASDAQ:FATE – Free Report) had its target price decreased by Barclays from $12.00 to $6.00 in a report published on Thursday morning, MarketBeat.com reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. FATE has been the topic of several other research reports. StockNews.com started coverage on shares of Fate Therapeutics […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Wedbush upped their Q3 2023 earnings per share estimates for Fate Therapeutics in a report issued on Wednesday, August 9th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.57) per share for the quarter, up from their […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Research analysts at HC Wainwright raised their Q3 2023 earnings estimates for Fate Therapeutics in a report released on Wednesday, August 9th. HC Wainwright analyst R. Burns now anticipates that the biopharmaceutical company will post earnings of ($0.58) per share for the quarter, up from their previous […]